NEW YORK, NY / ACCESS Newswire / February 1, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.

LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at ...

San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ:REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating. The stock, currently ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Regeneron (REGN) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led ...